Borgeson Blake sold $155K of RXRX
Borgeson Blake sold 40,000 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.88 ($0.16M total) on 2026-11-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is the first public report of this transaction, providing new information for traders.
Market read
Small insider sale may cause slight short‑term price pressure but is unlikely to move the broader market.
What to watch
The director retains a large stake, suggesting continued confidence.
Background
SEC Form 4 filing discloses insider transactions for public companies.
Ticker impact
Director Borgeson Blake sold 40,000 shares for $155,200 via a 10b5‑1 plan, reducing his holdings to 6,068,287 shares.
likely modest pressure as the market prices in the insider sale
Form 4 filing is a primary source; the sale amount is small but could be interpreted as a lack of confidence.
Market effects
Minimal impact on the biotech sector.
None
Low
Counterpoint
The sale may be routine under a pre‑arranged plan and not indicative of future performance.
Key entities
- companyRecursion Pharmaceuticals, Inc.
Biotech firm listed on NASDAQ under ticker RXRX.
- personBorgeson Blake
Director of Recursion Pharmaceuticals.




